These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 17472506

  • 1. Zoledronic acid treatment at home: safety data from an observational prospective trial.
    Tassinari D, Poggi B, Nicoletti S, Fantini M, Tamburini E, Possenti C, Sartori S.
    J Palliat Med; 2007 Apr; 10(2):352-8. PubMed ID: 17472506
    [Abstract] [Full Text] [Related]

  • 2. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA.
    J Clin Oncol; 2005 Dec 01; 23(34):8580-7. PubMed ID: 16314620
    [Abstract] [Full Text] [Related]

  • 3. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
    Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL.
    JAMA; 2017 Jan 03; 317(1):48-58. PubMed ID: 28030702
    [Abstract] [Full Text] [Related]

  • 4. Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
    Dhillon S, Lyseng-Williamson KA.
    Drugs; 2008 Jan 03; 68(4):507-34. PubMed ID: 18318568
    [Abstract] [Full Text] [Related]

  • 5. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
    Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V, Andriani A, D'Arena G, Balleari E, Pietrantuono G, Boccadoro M, Palumbo A, GIMEMA (Italian Group for Adult Hematologic Diseases)/Multiple Myeloma Working Party and the Italian Myeloma Network.
    Cancer; 2008 Oct 01; 113(7):1588-95. PubMed ID: 18683218
    [Abstract] [Full Text] [Related]

  • 6. [Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction].
    Lebret T, Mouysset JL, Lortholary A, Kouri CE, Bastit L, Ktiouet M, Khemaies S, Murraciole X, Guérif S.
    Bull Cancer; 2013 Mar 01; 100(3):247-57. PubMed ID: 23518272
    [Abstract] [Full Text] [Related]

  • 7. Zoledronic acid treatment for cancerous bone metastases: a phase IV study in Taiwan.
    Chiang PH, Wang HC, Lai YL, Chen SC, Yen-Hwa W, Kok CK, Ou YC, Huang JS, Huang TC, Chao TY.
    J Cancer Res Ther; 2013 Mar 01; 9(4):653-9. PubMed ID: 24518712
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G, Bordonaro R, Giotta F, Lorusso V, Scalone S, Vinaccia V, Rondena R, Amadori D.
    Oncologist; 2006 Mar 01; 11(7):841-8. PubMed ID: 16880243
    [Abstract] [Full Text] [Related]

  • 9. A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.
    Hong SJ, Cho KS, Cho HY, Ahn H, Kim CS, Chung BH.
    Yonsei Med J; 2007 Dec 31; 48(6):1001-8. PubMed ID: 18159593
    [Abstract] [Full Text] [Related]

  • 10. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y.
    Cancer J; 2001 Dec 31; 7(5):377-87. PubMed ID: 11693896
    [Abstract] [Full Text] [Related]

  • 11. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA.
    Expert Rev Anticancer Ther; 2009 Sep 31; 9(9):1211-8. PubMed ID: 19761424
    [Abstract] [Full Text] [Related]

  • 12. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K, Plosker GL.
    Pharmacoeconomics; 2008 Sep 31; 26(3):251-68. PubMed ID: 18282018
    [Abstract] [Full Text] [Related]

  • 13. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C, Kuchuk I, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Dranitsaris G, Dent S, Gertler S, Verma S, Song X, Simos S, Cella D, Clemons M.
    Breast Cancer Res Treat; 2016 Jan 31; 155(1):77-84. PubMed ID: 26643085
    [Abstract] [Full Text] [Related]

  • 14. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H.
    J Clin Oncol; 2011 Mar 20; 29(9):1125-32. PubMed ID: 21343556
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
    Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R, Barrett-Lee P, Ritchie D, Liversedge V, Hinsley S, Marshall H, AZURE investigators.
    Lancet Oncol; 2014 Aug 20; 15(9):997-1006. PubMed ID: 25035292
    [Abstract] [Full Text] [Related]

  • 16. Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer.
    Søe K, Delaissé JM, Jakobsen EH, Hansen CT, Plesner T.
    Acta Oncol; 2014 Apr 20; 53(4):547-56. PubMed ID: 24164102
    [Abstract] [Full Text] [Related]

  • 17. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid.
    Zuradelli M, Masci G, Biancofiore G, Gullo G, Scorsetti M, Navarria P, Tancioni F, Berlusconi M, Giordano L, Santoro A.
    Oncologist; 2009 May 20; 14(5):548-56. PubMed ID: 19411682
    [Abstract] [Full Text] [Related]

  • 18. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
    Lipton A, Cook RJ, Major P, Smith MR, Coleman RE.
    Oncologist; 2007 Sep 20; 12(9):1035-43. PubMed ID: 17914073
    [Abstract] [Full Text] [Related]

  • 19. Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction.
    Lebret T, Mouysset JL, Lortholary A, El Kouri C, Bastit L, Ktiouet M, Slimane K, Murraciole X, Guérif S.
    Support Care Cancer; 2013 Jun 20; 21(6):1613-20. PubMed ID: 23299561
    [Abstract] [Full Text] [Related]

  • 20. Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
    Crawford BS, McNulty RM, Kraut EH, Turowski RC.
    Cancer Invest; 2009 Dec 20; 27(10):984-8. PubMed ID: 19909013
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.